Pazopanib for Treating Uterine Leiomyosarcoma
The purpose of this study is to test any good and bad effects of the study drug pazopanib.
Uterine Leiomyosarcoma
DRUG: Pazopanib
Event free survival, To estimate the proportion of patients with persistent or recurrent uterine leiomyosarcoma, who survive event-free for at least 6 months (EFS \> 6 months; events associated with the endpoint are death, disease progression, or beginning a subsequent therapy) and the proportion of patients who have objective tumor response (complete or partial), treated with pazopanib., 6 months|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, To determine the nature and degree of toxicity of pazopanib in this cohort of patients, Every 4 weeks
Progression-free survival, To estimate progression-free survival in patients with recurrent or persistent leiomyosarcoma of the uterus, Every 3 months from time from study entry to time of progression or death, whichever occurs first, assessed up to 5 years|Event-free survival, To estimate event-free survival in patients with recurrent or persistent leiomyosarcoma of the uterus, Every 3 months from time of study entry totime of progression or death, whichever occurs first, assessed up to 5 years|Overall survival, To estimate overall survival in patients with recurrent or persistent leiomyosarcoma of the uterus, Every 3 months from time of study entry totime of progression or death, whichever occurs first, assessed up to 5 years
The purpose of this study is to test any good and bad effects of the study drug pazopanib.